Participated · Debt Financing · Dec 2025

HemaCell develops cell therapeutics centered on the platelet lineage, with a flagship product described as the world's first megakaryocyte injection and a pipeline of platelet injection candidates. The company aims to address blood supply shortages and reduce adverse consequences associated with blood transfusions, while pursuing platelet-derived therapeutics for aging-related indications. HemaCell is advancing multiple clinical trials for its lead program and plans to use recent Series B proceeds to support those trials and pipeline development. Management has signaled plans for a pre-IPO fundraising within the year to build manufacturing bases and expand production capacity. Founder Zhu Fangfang stated the company will continue steady, market- and clinic-driven development and rapidly pursue capital market milestones to enable eventual product launches.

Participated · Equity · Dec 2019

Huaqin Communication Technology is a China-based electronics production services provider and original design manufacturer that designs and produces communication and mobile devices. Founded in 2005, the company provides design and manufacturing services for mobile and communications equipment. The article reports Huaqin raised more than RMB1 billion (about $143m) in a financing round. That round valued the company at more than $2 billion. Investors named in the deal include Intel Capital, Qualcomm Ventures, Zhangjiang Hi-Tech, brokerage CMSC, CMB International and China Merchants Bank, as well as SinoKing Capital, Wise Road Capital and SummitView Capital. The article does not provide additional operating metrics or describe future plans. Huaqin Telecom is a Shanghai-based global original design manufacturer whose product lineup includes smartphones and tablets and extends to notebook computers, servers and Internet of Things devices. Led by President Vincent Qiu, the company serves global customers across multiple hardware categories. It received US$136M in a Series A financing to support its strategic initiatives. Huaqin plans to use the proceeds to develop its notebook computer and data center businesses, accelerate manufacturing automation and enhance vertical industry integration. Management says these moves are intended to bring added value to customers and expand its offerings beyond mobile devices. The company’s global footprint and product diversification position it to pursue growth across consumer and enterprise hardware segments.

Participated · Series D · Sep 2017

固生堂中医 operates a nationwide TCM clinic and primary-care chain with more than 30–31 outpatient clinics across 13 important cities and service coverage in 56 cities. The group employs roughly 1,500 TCM experts and reported about 3 million outpatient visits in 2016. Its core offering is standardized, chain‑operated TCM outpatient services combining on‑site clinics, IT systems, centralized herb procurement/quality control, and online consultation to bind patients to family‑doctor style care. Management has launched a “中医合伙人” (doctor‑partner) program that lets doctors take 30% equity in single stores, with guaranteed exit, pledgeable shares, dividend sharing, and suggested 8–10x return potential over eight years. Financially, the company has completed multiple financing rounds from domestic and foreign investors and reported total funding to date of over RMB1.7 billion. 固生堂 emphasizes integration with insurance and hospital networks, and positions itself as a mixed‑ownership, state‑backed chain to support China’s primary‑care and TCM reform goals.

Participated · Equity · Apr 2017

Didi Autonomous Driving is the self-driving arm of ride-hailing giant Didi that focuses on Level-4 autonomous vehicle technology and related AI systems. The company has spent nearly a decade building expertise in artificial intelligence, mass production, and large-scale operations for autonomous mobility. In 2025 it began full-scenario, fully unmanned road testing in Beijing and Guangzhou, with vehicles operating smoothly during rush hours, late nights, and heavy rain. A next-generation pre-installed autonomous vehicle, co-developed with GAC Aion, is scheduled for delivery by late 2025, after which Didi plans demonstration applications in both cities. The firm believes L4 autonomy will dramatically improve transportation safety, efficiency, and user experience while opening new employment opportunities. Fresh capital from its recent Series D round will be channelled into AI R&D and the accelerated rollout of L4 services. No revenue, user, or other operating metrics were disclosed in the announcement.